229 related articles for article (PubMed ID: 31088860)
1. Human PRPF40B regulates hundreds of alternative splicing targets and represses a hypoxia expression signature.
Lorenzini PA; Chew RSE; Tan CW; Yong JY; Zhang F; Zheng J; Roca X
RNA; 2019 Aug; 25(8):905-920. PubMed ID: 31088860
[TBL] [Abstract][Full Text] [Related]
2. Prp40 pre-mRNA processing factor 40 homolog B (PRPF40B) associates with SF1 and U2AF65 and modulates alternative pre-mRNA splicing in vivo.
Becerra S; Montes M; Hernández-Munain C; Suñé C
RNA; 2015 Mar; 21(3):438-57. PubMed ID: 25605964
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
[TBL] [Abstract][Full Text] [Related]
5. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
6. Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.
Hayashi Y; Zhang Y; Yokota A; Yan X; Liu J; Choi K; Li B; Sashida G; Peng Y; Xu Z; Huang R; Zhang L; Freudiger GM; Wang J; Dong Y; Zhou Y; Wang J; Wu L; Bu J; Chen A; Zhao X; Sun X; Chetal K; Olsson A; Watanabe M; Romick-Rosendale LE; Harada H; Shih LY; Tse W; Bridges JP; Caligiuri MA; Huang T; Zheng Y; Witte DP; Wang QF; Qu CK; Salomonis N; Grimes HL; Nimer SD; Xiao Z; Huang G
Cancer Discov; 2018 Nov; 8(11):1438-1457. PubMed ID: 30139811
[TBL] [Abstract][Full Text] [Related]
7. Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms.
Daniels NJ; Hershberger CE; Gu X; Schueger C; DiPasquale WM; Brick J; Saunthararajah Y; Maciejewski JP; Padgett RA
Cell Rep; 2021 Apr; 35(2):108989. PubMed ID: 33852859
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
9. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
10. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
11. An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing.
Zuccato E; Buratti E; Stuani C; Baralle FE; Pagani F
J Biol Chem; 2004 Apr; 279(17):16980-8. PubMed ID: 14966131
[TBL] [Abstract][Full Text] [Related]
12. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
Przychodzen B; Jerez A; Guinta K; Sekeres MA; Padgett R; Maciejewski JP; Makishima H
Blood; 2013 Aug; 122(6):999-1006. PubMed ID: 23775717
[TBL] [Abstract][Full Text] [Related]
13. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
14. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia regulates alternative splicing of HIF and non-HIF target genes.
Sena JA; Wang L; Heasley LE; Hu CJ
Mol Cancer Res; 2014 Sep; 12(9):1233-43. PubMed ID: 24850901
[TBL] [Abstract][Full Text] [Related]
16. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
17. Expression of leptin receptors in mononuclear cells from myelodysplastic syndromes and acute myeloid leukemias.
Tsiotra PC; Pappa V; Koukourava A; Economopoulos T; Tsigos C; Raptis SA
Acta Haematol; 2005; 114(2):71-7. PubMed ID: 16103628
[TBL] [Abstract][Full Text] [Related]
18. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
[TBL] [Abstract][Full Text] [Related]
19. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
[TBL] [Abstract][Full Text] [Related]
20. Using an exon microarray to identify a global profile of gene expression and alternative splicing in K562 cells exposed to sodium valproate.
Zhang XZ; Yin AH; Zhu XY; Ding Q; Wang CH; Chen YX
Oncol Rep; 2012 Apr; 27(4):1258-65. PubMed ID: 22200904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
